Literature DB >> 9342375

Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease.

H L Malech1, P B Maples, N Whiting-Theobald, G F Linton, S Sekhsaria, S J Vowells, F Li, J A Miller, E DeCarlo, S M Holland, S F Leitman, C S Carter, R E Butz, E J Read, T A Fleisher, R D Schneiderman, D E Van Epps, S K Spratt, C A Maack, J A Rokovich, L K Cohen, J I Gallin.   

Abstract

Little is known about the potential for engraftment of autologous hematopoietic stem cells in human adults not subjected to myeloablative conditioning regimens. Five adult patients with the p47(phox) deficiency form of chronic granulomatous disease received intravenous infusions of autologous CD34(+) peripheral blood stem cells (PBSCs) that had been transduced ex vivo with a recombinant retrovirus encoding normal p47(phox). Although marrow conditioning was not given, functionally corrected granulocytes were detectable in peripheral blood of all five patients. Peak correction occurred 3-6 weeks after infusion and ranged from 0.004 to 0.05% of total peripheral blood granulocytes. Corrected cells were detectable for as long as 6 months after infusion in some individuals. Thus, prolonged engraftment of autologous PBSCs and continued expression of the transduced gene can occur in adults without conditioning. This trial also piloted the use of animal protein-free medium and a blood-bank-compatible closed system of gas-permeable plastic containers for culture and transduction of the PBSCs. These features enhance the safety of PBSCs directed gene therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342375      PMCID: PMC23727          DOI: 10.1073/pnas.94.22.12133

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Update on chronic granulomatous diseases of childhood. Immunotherapy and potential for gene therapy.

Authors:  J I Gallin; H L Malech
Journal:  JAMA       Date:  1990-03-16       Impact factor: 56.272

2.  Autosomal recessive chronic granulomatous disease caused by deletion at a dinucleotide repeat.

Authors:  C M Casimir; H N Bu-Ghanim; A R Rodaway; D L Bentley; P Rowe; A W Segal
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

3.  Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease.

Authors:  K J Lomax; T L Leto; H Nunoi; J I Gallin; H L Malech
Journal:  Science       Date:  1989-07-28       Impact factor: 47.728

4.  Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase.

Authors:  B D Volpp; W M Nauseef; J E Donelson; D R Moser; R A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice.

Authors:  F M Stewart; R B Crittenden; P A Lowry; S Pearson-White; P J Quesenberry
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

6.  Peripheral blood progenitors as a target for genetic correction of p47phox-deficient chronic granulomatous disease.

Authors:  S Sekhsaria; J I Gallin; G F Linton; R M Mallory; R C Mulligan; H L Malech
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

7.  Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool.

Authors:  E S Buescher; D W Alling; J I Gallin
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two cytosolic components of the NADPH oxidase system.

Authors:  R A Clark; H L Malech; J I Gallin; H Nunoi; B D Volpp; D W Pearson; W M Nauseef; J T Curnutte
Journal:  N Engl J Med       Date:  1989-09-07       Impact factor: 91.245

9.  CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease.

Authors:  F Li; G F Linton; S Sekhsaria; N Whiting-Theobald; J P Katkin; J I Gallin; H L Malech
Journal:  Blood       Date:  1994-07-01       Impact factor: 22.113

Review 10.  Chronic granulomatous disease: the solving of a clinical riddle at the molecular level.

Authors:  J T Curnutte
Journal:  Clin Immunol Immunopathol       Date:  1993-06
View more
  60 in total

Review 1.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 2.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

3.  Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.

Authors:  Alice F Tarantal; Francesca Giannoni; C Chang I Lee; Jennifer Wherley; Teiko Sumiyoshi; Michele Martinez; Christoph A Kahl; David Elashoff; Stan G Louie; Donald B Kohn
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

Review 4.  Chronic granulomatous disease: lessons from a rare disorder.

Authors:  Brahm H Segal; Paul Veys; Harry Malech; Morton J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

5.  WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.

Authors:  Toshinao Kawai; Uimook Choi; Lanise Cardwell; Suk See DeRavin; Nora Naumann; Narda L Whiting-Theobald; Gilda F Linton; Jaehyun Moon; Philip M Murphy; Harry L Malech
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

6.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.

Authors:  Giorgia Santilli; Elena Almarza; Christian Brendel; Uimook Choi; Chiara Beilin; Michael P Blundell; Sneha Haria; Kathryn L Parsley; Christine Kinnon; Harry L Malech; Juan A Bueren; Manuel Grez; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

Review 7.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

Review 8.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 9.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

10.  Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.

Authors:  Elizabeth M Kang; Uimook Choi; Narda Theobald; Gilda Linton; Debra A Long Priel; Doug Kuhns; Harry L Malech
Journal:  Blood       Date:  2009-12-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.